Detalhe da pesquisa
1.
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Ann Oncol
; 35(1): 77-90, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37879444